Biotechnology company Triplet Therapeutics announced that it launched earlier this week with $59 million in financing as it develops ways to treat certain types of genetic disorders at their source.
The $59 million includes a $49 million Series A financing round led by MPM Capital and Pfizer Ventures U.S. Co-founder Atlas Venture seeded Triplet with $10 million and participated in the Series A, with Invus, Partners Innovation Fund and Alexandria Venture Investments also contributing.
Get the full story at our sister site, Drug Discovery & Development
